AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02167659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 23-32 mmHg compression sleeve with gauntlet
Description: A compression intervention consisting of a sleeve and gauntlet with 23-32mm of tension worn for four weeks that is initiated based on a BIS L-Dex change that is ≥6.5 units higher than pre-surgical baseline measure, or a tape measurement guided volume change in the affected arm that is between ≥5% and \<10% above pre-surgical baseline.
Study NCT02167659 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 23-32 mmHg compression sleeve with gauntlet
Description: A compression intervention consisting of a sleeve and gauntlet with 23-32mm of tension worn for four weeks that is initiated based on a BIS L-Dex change that is ≥6.5 units higher than pre-surgical baseline measure, or a tape measurement guided volume change in the affected arm that is between ≥5% and \<10% above pre-surgical baseline.
Study NCT02080130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics combination
Description: LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu
Study NCT02080130 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02937259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient self-admission to inpatient treatment
Description: Participants are given a contract whereby they are offered the possibility to admit themselves at will to the inpatient ward at the Stockholm Centre for Eating Disorders for a maximum of seven consecutive days at a time. They are also free to discharge themselves at any time. The participants may use this opportunity as often as they want to for a period of one year, or longer if the contract is renewed after one year.
Study NCT01569204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT01569204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Study NCT01569204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study NCT01569204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procarbazine
Study NCT02562040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Adenotonsillectomy (eAT)
Description: Standard clinical adenotonsillectomy within 4 weeks post randomization in addition to information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
Study NCT01569204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT01569204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Study NCT01569204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brentuximab Vedotin
Study NCT00427661 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Busulfan; Fludarabine; cyclosporine A and MMF
Description: Hematopoietic stem cell transplantation from a matched sibling or unrelated donor following a reduced intensity conditioning regimen
Study NCT03758924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73
Description: Liquid oral solution
Study NCT03758924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid oral solution
Study NCT01117597 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low RF exposure level
Description: Exposure with 1.5 W/kg
Study NCT01117597 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: sham exposure
Description: intervention with sham RF exposure
Study NCT01117597 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: high RF exposure
Description: intervention with high RF exposure
Study NCT04271384 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Combined neoadjuvant therapy consisting of nivolumab + SABR
Study NCT04323644 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Emergency or elective surgery
Study NCT02675140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZENTEL
Description: Children in Group 2 (n=62) received 400 mg single-dose albendazole (helmintic treatment)
Study NCT02675140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZENTEL and Vitamin A Soft Capsules
Description: Children in Group 3 (n=60) received a 200,000 IU vitamin A capsule combined with 400 mg single-dose albendazole once initially
Study NCT05181813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ginge-Cal
Description: Fill the infected root canal of of primary teeth with Gingerols extract and Calcium Hydroxide (Ginge-Cal)
Study NCT05181813 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metapex
Description: Fill the infected root canal of of primary teeth with Metapex
Study NCT02562040 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Watchful Waiting with Supportive Care (WWSC)
Description: Information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
Study NCT01758081 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day
Study NCT01758081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
Study NCT03477630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: intra-articular infiltration of 8 ml of autologous PRP every 15 days.
Study NCT03477630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: intra-articular infiltration of a single dose of HA
Study NCT01758081 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo
Study NCT01758081 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Study NCT05024838 — intervention group
Intervention type: OTHER
Intervention: Machine learning methods
Description: This is an observational study of the retrospective collection of patient data. Anesthesia-related factors such as anesthesiologist's expertise, injection site, patient position, the dosage of local anesthetics, needle size, the direction of needle bevel, and basic demographic information of the patients were used for data analysis. Patients less than 18 years old were excluded from this study. Twenty percent of the dataset was used as a testing dataset, and the remaining were used for model training. The investigators will utilize four machine learning algorithms as XGBoost (Extreme Gradient Boosting), AdaBoost (Adaptive Boosting), Random Forest (RF), and support vector machine (SVM). Model performances were evaluated visually with a confusion matrix.
Study NCT04297163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Remote CPAP monitoring, mobile app and voice mail
Study NCT01758081 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil placebo
Study NCT01758081 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: fish oil placebo
Study NCT03809793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: VO2 Max
Description: Assessment of maximum aerobic capacity.
Study NCT03809793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitor
Description: CGM sensor will be inserted to measure insulin sensitivity over a 24hr period.
Study NCT03809793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Glucose Monitor
Description: CGM sensor will be inserted to measure insulin sensitivity over a 24hr period.
Study NCT03809793 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Biopsies
Description: Participants will undergo muscle biopsies pre and post the hyperinsulinemic euglyceamic clamp from the vastus lateralis.
Study NCT01190176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gynaecological follow-up
Description: Subjects will receive a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to a maximum of four years.
Study NCT04297163 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In Hospital
Description: Face-to-face follow up
Study NCT03302611 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity-based Interventions
Description: Participants will be randomized to one of two physical activity-based interventions, surf or hike therapy.
Study NCT03302611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity-based Interventions
Description: Participants will be randomized to one of two physical activity-based interventions, surf or hike therapy.
Study NCT03363555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: A humanized monoclonal immunoglobulin.
Study NCT01243983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX211
Description: Subjects will be sequentially assigned to one of the following treatment arms in a 1:1 ratio:~* Treatment Arm A: voclosporin 0.4 mg/kg p.o. b.i.d., not to exceed 40 mg p.o. b.i.d.~* Treatment Arm B: placebo p.o. b.i.d.~Dosage Form:~• Soft gelatin capsule~Duration of treatment:~• 24 weeks
Study NCT01243983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX211
Description: Subjects will be sequentially assigned to one of the following treatment arms in a 1:1 ratio:~* Treatment Arm A: voclosporin 0.4 mg/kg p.o. b.i.d., not to exceed 40 mg p.o. b.i.d.~* Treatment Arm B: placebo p.o. b.i.d.~Dosage Form:~• Soft gelatin capsule~Duration of treatment:~• 24 weeks
Study NCT03601403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inhaler technique
Description: The first day of the intervention consisted primarily of ventilatory re-education. During the realization of the technique, he was videotaped with a Tablet so that later the patient could be seen and on the video to be able to give him the guidelines for the correction. On the second and third day of the intervention, ventilation re-education was performed and the inhalation technique was subsequently trained.
Study NCT01804205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h
Study NCT01804205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h
Study NCT00615316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guaraná
Description: Guaraná extract 75mg/day
Study NCT00615316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1tab/d
Study NCT03061591 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wholistic Turmeric capsules
Description: Oral capsules of wholistic Turmeric capsules (Pukka herbs) curcumin (each capsule 0.5100 m gr curcumin) for a total of 4 gr/d divided twice daily.
Study NCT03061591 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT06321653 — intervention group
Intervention type: RADIATION
Intervention: Hypofractionated radiotherapy scheme
Description: Hypofractionated radiotherapy scheme with 2.67Gy/fraction for 15 fractions. WBRT with simultaneous integrated boost to the tumor bed
Study NCT02542254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: 200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)
Study NCT02542254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: 200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)
Study NCT02542254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium
Description: 40 micrograms ipratropium administered using a pMDI
Study NCT02542254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium
Description: 40 micrograms ipratropium administered using a pMDI
Study NCT02542254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554
Description: 6 mg RPL554 administered using a nebuliser
Study NCT02542254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol matched placebo
Description: Placebo pMDI
Study NCT02542254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol matched placebo
Description: Placebo pMDI
Study NCT02542254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol matched placebo
Description: Placebo pMDI
Study NCT01014156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoprostenol
Description: titration up to 4 ng/kg/min
Study NCT02560415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Gaming Open Library for Intervention in Autism at Home plus Treatment as usual
Study NCT02560415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Treatment as usual
Study NCT02560415 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Treatment as usual
Study NCT04682964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulizer inhalation irrigation of the mucous membranes of the tonsils with a bacteriophage.
Description: Bacteriophage therapy using a liquid complex of pyobacteriophages (pyobacteriophage complex liquid - PСL). PСL was administered via nebulizer inhalation to irrigate the mucous membranes of the tonsils. In total, 5 ml of PCL was inhaled for up to 10 minutes once every 5 days.
Study NCT03957057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Carboxymaltose
Description: Intravenous iron carboxymaltose application
Study NCT02542254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ipratropium matched placebo
Description: Placebo pMDI
Study NCT02542254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium matched placebo
Description: Placebo pMDI
Study NCT03957057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside
Description: Inravenous iron isomaltoside application
Study NCT02542254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium matched placebo
Description: Placebo pMDI
Study NCT02542254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RPL554 matched placebo
Description: Nebulised placebo
Study NCT02542254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RPL554 matched placebo
Description: Nebulised placebo
Study NCT03768635 — intervention group
Intervention type: OTHER
Intervention: necrotizing external otitis
Description: description of necrotizing external otitis
Study NCT00918684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10mg tab daily
Study NCT03957057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulphate
Description: Oral ferrous sulphate application
Study NCT04422132 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 5 days Radiation Therapy (32.5 Gy in 5 fractions)
Description: Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.
Study NCT04422132 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 20 days Radiation therapy (55 Gy in 20 fractions)
Description: Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.
Study NCT03809793 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Muscle Biopsies
Description: Participants will undergo muscle biopsies pre and post the hyperinsulinemic euglyceamic clamp from the vastus lateralis.
Study NCT03809793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acipimox 250 MG
Description: Participants will be randomised into two groups. One group will be prescribed Acipimox that will be taken 1 hour prior to each exercise session. The other group will take no drug.
Study NCT01856283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib 300mg BID
Description: Nilotinib
Study NCT01190176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Subjects received 3 doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
Study NCT01190176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo control
Description: Subjects received 3 doses of the control \[Al(OH)3\] administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
Study NCT03876548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cadexomer Iodine Gel
Description: Subjects will apply gel product to keloid scar site every other day for 28 days following keloid scar revision surgery.
Study NCT03216291 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: biofeedback therapy
Description: Biofeedback therapy is a labor-intensive, multi-disciplinary, team approach for the management of patients with anorectal problems. Complete training sessions once a week for 6 weeks in the office.
Study NCT03216291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home Biofeedback therapy
Description: Biofeedback therapy is a labor-intensive, multi-disciplinary, team approach for the management of patients with anorectal problems, but instead of an office therapy, the subject will use a biofeedback device to gain strength in their anorectal muscles. This device will be taught how to use in the first session and then the subject will take it home to complete at least 1 session a day for 6 weeks.
Study NCT03189511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Description: Fluvastatin 40 mg twice daily per mouth for 14 days.
Study NCT03416933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: 2x10 ml of patient peripherical blood will be collected at D0, D15, D30, D90, D180, D270 and with progression or at the end of the follow-up at the 12th month.
Study NCT06042660 — intervention group
Intervention type: OTHER
Intervention: the prevalence of comorbid conditions
Description: analysis of history of comorbidities at the time of CML diagnosis
Study NCT03512223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intravenous and Perineural Dexamethasone for Brachial Plexus Block
Study NCT02128308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin and Streptomycin added
Study NCT02128308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin and Kanamycin added
Study NCT02134821 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery for lumbar spinal stenosis
Description: decompression with or without fusion for lumbar spinal stenosis
Study NCT00373256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 25 mg daily by oral capsules with titration up to 37.5 mg,
Study NCT00373256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
Study NCT00373256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Bevacizumab 10 mg/kg IV every 2 weeks.
Study NCT00373256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
Study NCT01957059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen Selection Phase Group 2
Description: All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 3 mg/kg
Study NCT01957059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen Selection Phase Group 3
Description: All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 4-6 mg/kg
Study NCT01957059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Phase Group 4
Description: All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3
Study NCT01957059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen Selection Phase Group 1 (COMPLETED)
Description: All doses of BMN053 have been administered as subcutaneous injections.